NCT00011908View on ClinicalTrials.gov

Humanized LL2IGG to Treat Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2001

Study Completion Date

January 31, 2003

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

hLL2 (Epratuzumab)

Trial Locations (1)

20892

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00011908 - Humanized LL2IGG to Treat Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter